JAZBI Filler
Pre-clinical- Indications
- Bone defects
Company intelligence / Profile preview
SDIP Innovations has developed a patented, programmable bioresorbable implant platform called JAZBI™, designed to mimic natural bone remodeling for healing fractured bones. Their compounds fully resorb into the body without leaving acidic or basic by-products, aiming to avoid inflammation and promote optimal tissue regeneration. The company has secured over $11M in funding through private investments and grants, including significant recognition from Australian innovation awards. Initial products include the JAZBI™ bone filler and Osseo Dispenser, with ISO-certified cleanroom manufacturing established in Australia. No published clinical trial results are available as of June 2025.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SDIP Innovations.